Article Sidebar
Views pdf: 95
NON HDL-C CONTROL IN OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS AFTER ACHIEVING LDL-C TARGET
Main Article Content
Abstract
Introduction: Type 2 diabetes is a prevalent disorder in the community and a significant cardiovascular risk factor. Controlling LDL-C in this population is a treatment requirement. After achieving LDL-C goals, residual dyslipidemia risk factors such as non HDL-C is recommended for optimal control. Objective: The study aimed to determine the control rates of non HDL-C in outpatients with type 2 diabetes mellitus after achieving LDL-C target. Method: A retrospective study was conducted at the endocrinology and cardiology clinics of Nhan Dan Gia Dinh Hospital from March 2021 to March 2022. Results: 103 patients with type 2 diabetes at high and above cardiovascular risk with controlled LDL-C participated. The control rates for non HDL-C (< 2.6 mmol/L and < 2.2 mmol/L for high risk and very high risk, respectively) was 89,3%. Statin therapy accounted for 99%, mostly as monotherapy. Only 9,7% had high-intensity statin prescription. Conclusion: The control rate of non HDL-C is suboptimal in the outpatient management of type 2 diabetes mellitus that need more proper attention.
Article Details
Keywords
Type 2 diabetes mellitus, non HDL-C, statin
References
2. Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Sandeep R. Das, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Mikhail Kosiborod, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay; on behalf of the American Diabetes Association, 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care 1 January 2023; 46 (Supplement_1): S158–S190.
3. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.
4. Hansen MK, Mortensen MB, Warnakula Olesen KK, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. Lancet Reg Health Eur. 2023 Nov 4;36:100774.
5. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2 (Ban hành kèm theo Quyết định số 5481/QĐ-BYT ngày 30 tháng 12 năm 2020). https://daithaoduong.kcb.vn/huong-dan-chan-doan-va-dieu-tri-dai-thao-duong-tip-2
6. Al Slail FY, Abid O, Assiri AM, Memish ZA, Ali MK. Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. J Epidemiol Glob Health. 2016 Mar;6(1):29-36.
7. Regassa LD, Tola A, Ayele Y. Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia. Front Public Health. 2021 Feb 5;8:532719.
8. Anne L. Peters; Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes. Clin Diabetes 1 January 2008; 26 (1): 3–7.
9. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005 Aug;28(8):1916-21.